Published in Nat Med on August 17, 2014
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata | NCT01950780
Androgenetic Alopecia and the JAK-STAT Pathway | NCT03694067
Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat Chem Biol (2016) 1.49
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine (2015) 1.15
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol (2015) 1.11
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol (2015) 1.00
dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration. Cell Stem Cell (2015) 0.99
IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol (2015) 0.94
Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv (2015) 0.89
Flame Hair. Skin Appendage Disord (2015) 0.87
Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution. Cell Syst (2015) 0.82
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. Case Rep Dermatol (2016) 0.81
The Diagnosis and Treatment of Hair and Scalp Diseases. Dtsch Arztebl Int (2016) 0.81
Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report. Case Rep Dermatol (2016) 0.80
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight (2016) 0.80
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheumatol (2017) 0.80
Hair regrowth in alopecia areata patients following Stem Cell Educator therapy. BMC Med (2015) 0.79
Novel therapies for memory cells in autoimmune diseases. Clin Exp Immunol (2015) 0.79
CD49a Expression Defines Tissue-Resident CD8(+) T Cells Poised for Cytotoxic Function in Human Skin. Immunity (2017) 0.79
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight (2016) 0.78
Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine (2016) 0.78
Crisp1 and alopecia areata in C3H/HeJ mice. Exp Mol Pathol (2014) 0.78
Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells. Front Immunol (2016) 0.78
Inhibiting Janus kinases to treat alopecia areata. Nat Med (2014) 0.77
Transfer of Alopecia Areata to C3H/HeJ Mice Using Cultured Lymph Node-Derived Cells. J Invest Dermatol (2015) 0.76
Autoimmune disease: Getting to the root of hair loss in alopecia. Nat Rev Drug Discov (2014) 0.76
Dietary vitamin A regulates wingless-related MMTV integration site signaling to alter the hair cycle. Exp Biol Med (Maywood) (2014) 0.76
Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata. J Invest Dermatol (2016) 0.76
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol (2016) 0.76
Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr (2016) 0.76
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Clin Case Rep (2015) 0.75
JAK inhibitors and myelofibrosis, Einstein and ruxolitinib. Haematologica (2015) 0.75
Skin Diseases in Laboratory Mice: Approaches to Drug Target Identification and Efficacy Screening. Methods Mol Biol (2016) 0.75
Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol (2015) 0.75
Drug discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov (2015) 0.75
The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol (2015) 0.75
Novel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT). Allergo J Int (2015) 0.75
Two birds that exclude each other: the Renbök phenomenon. J Invest Dermatol (2014) 0.75
Multilayered T-cell memory in human skin. Ann Transl Med (2015) 0.75
CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata. J Immunol (2016) 0.75
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther (2016) 0.75
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. PLoS One (2016) 0.75
Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev (2016) 0.75
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata. EBioMedicine (2015) 0.75
3-Deoxysappanchalcone Promotes Proliferation of Human Hair Follicle Dermal Papilla Cells and Hair Growth in C57BL/6 Mice by Modulating WNT/β-Catenin and STAT Signaling. Biomol Ther (Seoul) (2016) 0.75
Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. J Autoimmun (2017) 0.75
Alopecia Areata: An Update on Treatment Options for Children. Paediatr Drugs (2017) 0.75
Alopecia areata. Nat Rev Dis Prim (2017) 0.75
Soluble MICB in Plasma and Urine Explains Population Expansions of NKG2D(+)CD4 T Cells Inpatients with Juvenile-Onset Systemic Lupus Erythematosus. Open J Immunol (2017) 0.75
Ruxolitinib found to cause eyelash growth: a case report. J Med Case Rep (2017) 0.75
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22
Interleukin 15: biology and relevance to human disease. Blood (2001) 4.47
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics (2003) 2.92
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol (2011) 2.59
Alopecia areata. N Engl J Med (2012) 2.56
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
Molecular definition of the identity and activation of natural killer cells. Nat Immunol (2012) 1.97
Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation. Nat Immunol (2013) 1.96
Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol (1994) 1.78
Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis (2013) 1.64
Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol (1998) 1.46
Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest (1998) 1.27
A 'hairy' privilege. Trends Immunol (2005) 1.21
Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol (2007) 1.18
Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol (2005) 1.16
Alopecia areata induced in C3H/HeJ mice by interferon-gamma: evidence for loss of immune privilege. J Invest Dermatol (2005) 1.13
Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell Immunol (1996) 1.13
Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol (2006) 1.10
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol (2012) 1.09
Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J Immunol (2010) 1.07
Companies hope for kinase inhibitor JAKpot. Nat Rev Drug Discov (2011) 0.93
Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS One (2014) 0.92
Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J Invest Dermatol (2005) 0.88
Interleukin-2 receptor alpha-chain expression in patients with alopecia areata. Acta Dermatovenerol Croat (2004) 0.86
αβ T cell antigen receptor recognition of CD1a presenting self lipid ligands. Nat Immunol (2015) 0.98
Genetics of structural hair disorders. J Invest Dermatol (2012) 0.89
Identification of distinct mutations in AAGAB in families with type 1 punctate palmoplantar keratoderma. J Invest Dermatol (2014) 0.79
JAK-STAT Signaling Jump Starts the Hair Cycle. J Invest Dermatol (2016) 0.75
Genetics of Structural Hair Disorders. J Invest Dermatol (2012) 0.75